Swipe om te navigeren naar een ander artikel
Effectiveness of antidepressants is generally comparable between and within classes. However, real-world studies on antidepressant treatment and its consequences on the overall quality of life and mental health of individuals are limited. The purpose of this study was to examine the association of specific class of antidepressants with the health-related quality of life, psychological distress and self-reported mental health of individuals suffering from depression who are on monotherapy.
This retrospective, longitudinal study included individuals with depression who were on antidepressant monotherapy, using data from 2008 to 2011 Medical Expenditure Panel Survey (MEPS). Changes in health-related quality of life, self-reported mental health and psychological distress over a year’s time were observed. A multinomial logistic regression model was built to examine the association between the class of antidepressant medications and the dependent variables.
A total of 688 adults met the study inclusion criteria. No significant difference was observed in the change in Physical Component Summary (PCS), self-reported mental health and psychological distress based on the class of antidepressants. However, individuals on serotonin–norepinephrine reuptake inhibitors (SNRIs) (OR 0.337, 95 % CI 0.155–0.730) were significantly less likely to show improvement on Mental Component Summary (MCS) scores as compared to those on selective serotonin reuptake inhibitors (SSRIs).
The study findings suggest that practitioners should be aware of the differences in the health-related quality of life of those taking SSRIs versus other classes of antidepressants. Further research needs to be done to determine the reason for SSRIs to show greater improvement on mental health as compared to SNRIs.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Centers for Disease Control and Prevention. (2011). An estimated 1 in 10 U.S. adults report depression. Retrieved August 22, 2011 from http://www.cdc.gov/Features/dsDepression.
Wells, K. B., Stewart, A., Hays, R. D., et al. (1989). The functioning and well-being of depressed patients: results from the Medical Outcomes Study. Journal of the American Medical Association, 262, 916–919.
National Center for Health Statistics. Health, U. S. (2010). With, & special feature on death and dying. Table 95. Hyattsville, M. http://www.cdc.gov/nchs/data/hus/hus10.pdf.
Centres for Medicare and Medicaid & Medicaid Services. (2013). Antidepressant medications: Use in adults, from http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ad-adult-factsheet.pdf.
American Psychiatric Association. (2010). Practice guideline for the treatment of patients with major depressive disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.
Stark, P., & Hardison, C. D. (1985). A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. Journal of Clinical Psychiatry, 46(3 (Sect. 2)), 53–58. PubMed
Workman, E., & Short, D. (1993). Atypical antidepressants versus imipramine in the treatment of major depression. Journal of Clinical Psychiatry, 54, 5–12. PubMed
Mendels, J., Reimherr, F., Marcus, R. N., et al. (1995). A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. Journal of Clinical Psychiatry, 56(6 Suppl.), 30–36. PubMed
Preskorn, S. H. (1995). Comparison of the tolerability of bupropion fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Journal of Clinical Psychiatry, 56(Suppl.), 12–21. PubMed
Bolton, J. M., & Robinson, J. (2010). Population-attributable fractions of Axis I and Axis II mental disorders for suicide attempts: Findings from a representative sample of the adult, noninstitutionalized US population. American Journal of Public Health, 100(12), 2473–2480. CrossRefPubMedPubMedCentral
Lorenz, R. A., Whitley, H. P., & McCoy, E. K. (2010). Safety of varenicline in patients with mental illness. Primary Psychiatry, 17(9), 60–66.
AHRQ. (2011). MEPS-HC sample design and collection process. Rockville: AHRQ. [cited 2011 17th February]. http://www.meps.ahrq.gov/mepsweb/survey_comp/hc_data_collection.jsp.
AHRQ. (2008). MEPS HC-120: 2008 Medical Conditions. Center for Financing, Access, and Cost Trends540. Gaither Road Rockville, MD: Agency for Healthcare Research and Quality; 2010. cited 2012 9th August]. http://meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h120/h120doc.shtml.
Khanna, R., Bhanegaonkar, A., Colsher, P., Madhavan, S. S., & Halverson, J. (2009). Breast cancer screening, incidence, and mortality in West Virginia. West Virginia Medical Journal, 105(S1), 24–32. PubMed
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41, 582–592. PubMed
Al-Ruthia, Y. S., Hong, S. H., & Solomon, D. (2015). Do depressed patients on adjunctive atypical antipsychotics demonstrate a better quality of life compared to those on antidepressants only? A comparative cross-sectional study of a nationally representative sample of the US population. Research in Social and Administrative Pharmacy, 11(2), 228–240. CrossRefPubMed
Selective serotonin and norepinephrine reuptake inhibitors (SNRI) for patients with depression: Executive summary of final report A05-20A, Version 1.0 (2005). In Institute for Quality and Efficiency in Health Care: Executive Summaries. Cologne, Germany: IQWiG (Institute for Quality and Efficiency in Health Care). https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0049661.
Taylor, D., Paton, C., & Kapur, S. (2012). The South London and Maudsley NHS FoundationTrust Prescribing Guidelines in Psychiatry (11th ed.). London: Wiley.
Maity, N., Ghosal, M. K., Gupta, A., Sil, A., Chakraborty, S., & Chatterjee, S. (2014). Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial. Indian Journal of Pharmacology, 46(4), 433–437. doi: 10.4103/0253-7613.135959. CrossRefPubMedPubMedCentral
Nordstrom, G., Danchenko, N., Despiegel, N., & Marteau, F. (2012). Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder. Value Health, 15(2), 231–239. doi: 10.1016/j.jval.2011.09.011. CrossRefPubMed
Kornstein, S. G., Li, D., Mao, Y., Larsson, S., Andersen, H. F., & Papakostas, G. I. (2009). Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: Integrative analysis of four double-blind, randomized clinical trials. CNS Spectrums, 14(06), 326–333. CrossRefPubMed
Cipriani, A., Brambilla, P., Furukawa, T. A., Geddes, J., Gregis, M., & Hotopf, M., et al. (2005). Fluoxetine versus other types of pharmacotherapy for depression. The Cochrane Database of Systematic Reviews, (4), CD004185–CD004185. doi: 10.1002/14651858.CD004185.pub2.
Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., & Gaynes, B. N. (2010). Health-related quality of life in depression: A STAR* D report. Annals of Clinical Psychiatry, 22(1), 43–55. PubMed
- Assessment of health-related quality of life, mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression
- Springer International Publishing